Go to AAD Home
Donate For Public and Patients Store Search

Go to AAD Home
Welcome!
Advertisement
Advertisement

2023 Annual Meeting: Industry Product Sessions


AM23 Hero image

These unique sessions provide exhibiting companies the opportunity to:

  • Present new research findings on products

  • Detail products

  • Conduct demonstrations

  • Highlight new products

These sessions are solely promotional and are not eligible for CME credit.

Session schedule

THEATER 1

Friday, March 17, 2023 | Exhibit Hall F

10:30 a.m. - 11:15 a.m.

When Self-Identity is Challenged in Dermatology: Clinical Implications for Alopecia Areata & Vitiligo

This multidisciplinary session will bring attention to the highly individualized burden of disease in AA and vitiligo in the context of culture, race, and religion, and the associated clinical implications.

Pfizer logo

12:00 p.m. - 12:45 p.m.

Uncovering the Critical Role of OX40 Signaling in Orchestrating Inflammation in Atopic Dermatitis

OX40 signaling can play a critical role in AD pathogenesis by driving T-cell-mediated effector and memory responses that orchestrate inflammation and disease chronicity.

Amgen and Kyowa Kirin joint logo

1:30 p.m. - 2:15 p.m.

The Shades of Atopic Dermatitis in Skin of Color

Learn more about distinctive ways that atopic dermatitis (AD) may present in patients with skin of color. Learn about a treatment option that may help appropriate patients with uncontrolled moderate-to-severe AD.

Sanofi Regeneron logo

3:00 p.m. - 3:45 p.m.

An Adjuvant Treatment Option for Certain Stages of Melanoma

Understand the recurrence rates in certain stages of melanoma from retrospective studies. Review efficacy and safety data for an adjuvant treatment for certain patients with completely resected melanoma.

Merck logo
THEATER 1

Saturday, March 18, 2023 | Exhibit Hall F

10:30 a.m. - 11:15 a.m.

A new game changer for the treatment of epidermal pigmentation: Reepot®

Reepot® is the world’s first target laser based on Q-switch 532nm, and control the hemoglobin chromophore that is related to side effects through a super-cooling control device by VSLS technology.

ilooda logo

12:00 p.m. - 12:45 p.m.

Start Today, Without Delay: An Oral Treatment For Any Adult Patient With Plaque Psoriasis Regardless of Severity

Exploring the systemic nature and burden of plaque psoriasis, regardless of the extent of skin involvement. Highlighting earlier treatment considerations for appropriate patients who may need something more.

Amgen logo

1:30 p.m. - 2:15 p.m.

Diagnosing and Assessing Prurigo Nodularis

Learn about the clinical presentation and diagnostic workup of prurigo nodularis (PN).

Sanofi Regeneron logo
THEATER 1

Sunday, March 19, 2023 | Exhibit Hall F

10:30 a.m. - 11:15 a.m.

Alopecia Areata (AA): What You Need to Know

Reviews AA pathophysiology and the role of immune cells and inflammatory cytokines, provides an overview of methods to evaluate disease severity, and discusses the patient burden beyond hair loss.

Pfizer logo

12:00 p.m. - 12:45 p.m.

Targeted Biome Bacteriolysis - Novel Endolysin Addressing Undesired Staphylococcus aureus Colonization

Presented by GladskinMD

Blank logo placeholder

1:30 p.m. - 2:15 p.m.

A Breakthrough Treatment for Adult Patients With Generalized Pustular Psoriasis Flares

This program will review the diagnosis and treatment of GPP flares.

Boehringer Ingelheim Pharmaceuticals, Inc. logo
THEATER 2

Friday, March 17, 2023 | Exhibit Hall F

10:30 a.m. - 11:15 a.m.

Discussion on an Oral Treatment Option for Adult Patients with Moderate-to-Severe Plaque Psoriasis

This program describes the efficacy and safety profile of an oral product. You will learn more about the pivotal clinical trials, product function, and patient support services.

Bristol Myers Squibb logo

12:00 p.m. - 12:45 p.m.

Real Patient Stories: Taltz® (ixekizumab) Treatment Outcomes

This presentation includes a clinical overview of disease manifestations, clinical efficacy, and safety outputs from relevant pivotal trials. The facilitator will provide clinical insights and be available for a live Q&A session.

Lilly logo

3:00 p.m. - 3:45 p.m.

A game-changing discovery for Skincare: Novel postbiotic bioactive Urolithin A (MitopureR) slows both intrinsic and extrinsic skin aging

Topical solutions that are safe and improve cellular health during aging are needed. Findings on Urolithin A, a postbiotic molecule that reverses intrinsic and extrinsic skin aging will be presented.

Timeline logo
THEATER 2

Saturday, March 18, 2023 | Exhibit Hall F

10:30 a.m. - 11:15 a.m.

Join Pfizer: Learn About an Oral RX Treatment for Moderate-to-Severe Atopic Dermatitis

Pfizer logo

12:00 p.m. - 12:45 p.m.

Step into Possibility: Discover Olumiant - The first FDA-approved systemic treatment for adults with severe alopecia areata (AA)

This presentation includes a clinical overview of disease manifestations, clinical efficacy, and safety outputs from relevant pivotal trials. The facilitator will provide clinical insights and be available for a live Q&A session.

Lilly logo

1:30 p.m. - 2:15 p.m.

Creating a World-First ‘Matrikine’ Peptide Blend with No7

With 86 years of innovation, No7 is unveiling a novel matrix-derived peptide blend created with skin scientists at the University of Manchester; following 15 years of research into skin aging and repair.

No7

3:00 p.m. - 3:45 p.m.

The newest effective and tolerable solution for Rosacea

Galderma logo
THEATER 2

Sunday, March 19, 2023 | Exhibit Hall F

10:30 a.m. - 11:15 a.m.

Join us to learn about the multidisciplinary management of advanced CSCC and locally advanced BCC.

Regeneron is a leading science-based biopharmaceutical company that invents, develops and commercializes medicines to treat serious medical conditions.

Regeneron Logo

12:00 p.m. - 12:45 p.m.

ParaPRO’s Thought Leader AI

Join Dr. Christina Feser, DO, FAAD, FAOCD as she engages “live” with digital human avatars of the leading experts on the topic of scabies. It’s the future of scientific exchange!

ParaPro logo

Advertisement